uniQure CEO Matthew Kapusta Sells Shares

Matthew Kapusta, the CEO and Managing Director of uniQure N.V., sold 4,128 shares of the company on June 24, 2026. This insider transaction was not part of a pre-planned trading scheme. On the day the sale was reported, shares of uniQure traded around $47.84 on the NasdaqGS.

Other Institutional Activity in uniQure

Several institutional investors have recently adjusted their holdings in uniQure. Avoro Capital Advisors LLC reduced its stake by 190,405 shares, now holding about 5,959,595 shares valued at $97.4 million. Aberdeen Group PLC increased its position by 1,627,746 shares, bringing its total to 5,306,386 shares worth approximately $86.8 million. JPMorgan Chase & Co decreased its holdings by 97,160 shares, ending with 2,837,466 shares valued at about $41.8 million. Two Sigma Investments, LP added 1,224,587 shares, now owning 2,675,871 shares worth roughly $43.8 million. Lastly, RTW Investments, LP trimmed its stake by 1,125,106 shares, holding 2,586,356 shares valued at $42.3 million.

uniQure N.V. Stock Down 2.5%

On Saturday, shares of NasdaqGS:QURE traded near $47.84. uniQure, a biotechnology company, has a market cap of around $3.38 billion. The stock's 52-week range is between $8.73 and $71.50. Its 50-day moving average stands at $26.62, while the 200-day moving average is $28.13. The company has a beta of 1.001, indicating its stock price is about as volatile as the overall market. uniQure also maintains a robust current ratio of 10.40 and a quick ratio of 9.97, though its debt-to-equity ratio is quite high at 365.37.

Analysts Set New Price Targets

On June 25, 2026, Mizuho maintained a 'buy' rating on uniQure with a price target of $68. Barclays upgraded the stock to a 'buy' with a $65 target on June 18. Goldman Sachs kept a 'hold' rating with a $46 target on the same day. Leerink Partners, RBC Capital, and HC Wainwright & Co. all maintained 'buy' ratings with targets of $70, $65, and $50, respectively. The consensus among analysts is a 'strong buy', with a mean target price of $61.59 from 11 analysts.

About uniQure

uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands. It focuses on developing treatments for patients with rare and serious diseases. Its flagship product, HEMGENIX, helps those with hemophilia B by enabling them to produce factor IX, reducing bleeding risks. The company is also advancing gene therapy candidates like AMT-130 for Huntington's disease and AMT-260 for epilepsy. uniQure was founded in 1998 and continues to innovate in the healthcare sector.

Bottom Line

Matthew Kapusta's recent sale of shares in uniQure is part of the regular insider trading activity tracked by investors. While such sales can attract attention, they don't necessarily signal any change in the company's outlook. Investors and analysts continue to keep a close eye on uniQure, especially given its innovative treatments and ongoing research in gene therapy. As always, 13F filings and insider transactions provide a backward-looking view and may not reflect the current sentiment or strategy of the insiders.